Breast Cancer Updates from SABCS 2024

In this week’s podcast, we will discuss the most recent developments in breast cancer from the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX. Join us as renowned experts exclusively speak with us on highly anticipated findings from clinical trials across different breast cancer subtypes. Gaia Griguolo from University of Padova in Italy, first discusses the PATINA trial, which investigated the addition of palbociclib to anti-HER2 and endocrine therapy in HR+/HER2+ breast cancer and Puneet Singh from The University of Texas MD Anderson Cancer Center comments on the COMET trial, which compared active monitoring with surgical management in low-risk ductal carcinoma in situ (DCIS). Elisa Agostinetto from Jules Bordet Institute subsequently gives an overview of findings from the Phase II DECRESCENDO trial of anthracycline-free treatment for HER2-positive, HR-negative, node-negative early breast cancer. Icro Meattini closes this episode with results from the EUROPA and FAST-Forward studies.